- Home
- ANNX vs KNOP Comparison
ANNX vs KNOP Comparison
Compare ANNX & KNOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- KNOP
- Stock Information
- Founded
- ANNX 2011
- KNOP 2013
- Country
- ANNX United States
- KNOP United Kingdom
- Employees
- ANNX N/A
- KNOP N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- KNOP Marine Transportation
- Sector
- ANNX Health Care
- KNOP Consumer Discretionary
- Exchange
- ANNX Nasdaq
- KNOP Nasdaq
- Market Cap
- ANNX 253.8M
- KNOP 243.9M
- IPO Year
- ANNX 2020
- KNOP 2013
- Fundamental
- Price
- ANNX $2.06
- KNOP $8.30
- Analyst Decision
- ANNX Strong Buy
- KNOP
- Analyst Count
- ANNX 5
- KNOP 0
- Target Price
- ANNX $13.00
- KNOP N/A
- AVG Volume (30 Days)
- ANNX 1.2M
- KNOP 56.6K
- Earning Date
- ANNX 08-14-2025
- KNOP 09-25-2025
- Dividend Yield
- ANNX N/A
- KNOP 1.25%
- EPS Growth
- ANNX N/A
- KNOP N/A
- EPS
- ANNX N/A
- KNOP 0.19
- Revenue
- ANNX N/A
- KNOP $320,026,000.00
- Revenue This Year
- ANNX N/A
- KNOP $9.01
- Revenue Next Year
- ANNX N/A
- KNOP $0.42
- P/E Ratio
- ANNX N/A
- KNOP $44.13
- Revenue Growth
- ANNX N/A
- KNOP 8.76
- 52 Week Low
- ANNX $1.29
- KNOP $5.28
- 52 Week High
- ANNX $7.85
- KNOP $8.37
- Technical
- Relative Strength Index (RSI)
- ANNX 38.44
- KNOP 77.32
- Support Level
- ANNX $2.06
- KNOP $7.18
- Resistance Level
- ANNX $2.36
- KNOP $7.52
- Average True Range (ATR)
- ANNX 0.17
- KNOP 0.27
- MACD
- ANNX -0.03
- KNOP 0.09
- Stochastic Oscillator
- ANNX 1.52
- KNOP 95.56
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.